blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3301186

EP3301186 - METHOD, SEQUENCES, COMPOSITIONS AND KIT FOR DETECTION OF MUTATIONEN IN THE PROMOTER OF THE GENE HTERT [Right-click to bookmark this link]
Former [2018/14]METHOD, SEQUENCES, COMPOSITIONS AND KIT FOR DETECTION OF MUTATIONS IN THE HTERT
[2020/49]
StatusNo opposition filed within time limit
Status updated on  03.12.2021
Database last updated on 23.09.2024
FormerThe patent has been granted
Status updated on  25.12.2020
FormerGrant of patent is intended
Status updated on  25.11.2020
FormerExamination is in progress
Status updated on  05.06.2020
FormerRequest for examination was made
Status updated on  02.03.2018
FormerThe international publication has been made
Status updated on  04.11.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT
published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
IPATIMUP ( Instituto de Patologia e Imunologia Molecular da Universidade do Porto
Rua Dr. Roberto Frias s/n
4200-465 Porto / PT
[2018/14]
Inventor(s)01 / SOARES DIAS FERREIRA, Ana Paula
Rua João das Regras 67 1º
4000-292 Porto / PT
02 / MARQUES PRAZERES, Hugo João
Qta S. Francisco
Lote 54 2º Esq.
3200-343 Serpins / PT
03 / ALVES SALGADO, Catarina Miguel
Rua Eça De Queirós 140
2º Esq
Gondomar
4510-555 Fânzeres / PT
04 / MONTEIRO BATISTA, Rui Pedro
Rua Fonte da Pereira B
5000-105 Vila Real / PT
05 / RICO DE OLIVEIRA VINAGRE, João Pedro
Rua Visconde de Ovar 152
3880-272 Ovar / PT
 [2018/14]
Representative(s)Ferreira Pinto, Francisca
Garrigues IP, Unipessoal Lda.
Av. da República, 25-1°
1050-186 Lisboa / PT
[2018/14]
Application number, filing date16732356.702.05.2016
[2018/14]
WO2016PT50007
Priority number, datePT2015010841930.04.2015         Original published format: PT 2015108419
[2018/14]
Filing languagePT
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016175672
Date:03.11.2016
Language:PT
[2016/44]
Type: A1 Application with search report 
No.:EP3301186
Date:04.04.2018
Language:EN
[2018/14]
Type: B1 Patent specification 
No.:EP3301186
Date:27.01.2021
Language:EN
[2021/04]
Search report(s)International search report - published on:EP03.11.2016
ClassificationIPC:C12Q1/6886
[2020/49]
CPC:
C12Q1/6886 (EP,RU,US); C12N15/65 (PT); C12N15/52 (PT);
C12Q1/68 (PT); C12Q1/6806 (RU); C12Q2600/156 (EP,US)
Former IPC [2018/14]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/14]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:METHODEN, SEQUENZEN, ZUSAMMENSETZUNGEN UND KIT ZUM NACHWEIS VON MUTATIONEN IM PROMOTER DES HTERT GENS[2020/49]
English:METHOD, SEQUENCES, COMPOSITIONS AND KIT FOR DETECTION OF MUTATIONEN IN THE PROMOTER OF THE GENE HTERT[2020/49]
French:MÉTHODE, SÉQUENCES, COMPOSITIONS ET TROUSSE POUR LA DÉTECTION DE MUTATIONS DANS LE PROMOTEUR DU GÈNE HTERT[2018/14]
Former [2018/14]VERFAHREN, SEQUENZEN, ZUSAMMENSETZUNGEN UND KIT ZUR DETEKTION VON MUTATIONEN IN DER HTERT
Former [2018/14]METHOD, SEQUENCES, COMPOSITIONS AND KIT FOR DETECTION OF MUTATIONS IN THE HTERT
Entry into regional phase29.11.2017Translation filed 
29.11.2017National basic fee paid 
29.11.2017Designation fee(s) paid 
29.11.2017Examination fee paid 
Examination procedure29.11.2017Examination requested  [2018/14]
29.11.2017Date on which the examining division has become responsible
08.06.2018Amendment by applicant (claims and/or description)
09.06.2020Despatch of a communication from the examining division (Time limit: M04)
01.10.2020Reply to a communication from the examining division
26.11.2020Communication of intention to grant the patent
16.12.2020Fee for grant paid
16.12.2020Fee for publishing/printing paid
16.12.2020Receipt of the translation of the claim(s)
Opposition(s)28.10.2021No opposition filed within time limit [2022/01]
Fees paidRenewal fee
01.03.2018Renewal fee patent year 03
12.03.2019Renewal fee patent year 04
12.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.05.2016
AL27.01.2021
AT27.01.2021
CY27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
MK27.01.2021
MT27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
IE02.05.2021
PT27.05.2021
[2024/41]
Former [2024/22]HU02.05.2016
AL27.01.2021
AT27.01.2021
CY27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
MK27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
IE02.05.2021
PT27.05.2021
Former [2023/30]HU02.05.2016
AL27.01.2021
AT27.01.2021
CY27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
IE02.05.2021
PT27.05.2021
Former [2023/29]HU02.05.2016
AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
IE02.05.2021
PT27.05.2021
Former [2022/21]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
IE02.05.2021
PT27.05.2021
Former [2022/13]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SI27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2022/07]AL27.01.2021
AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/50]AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RO27.01.2021
RS27.01.2021
SK27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/48]AT27.01.2021
CZ27.01.2021
EE27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/46]AT27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
SM27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/39]AT27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
PL27.01.2021
RS27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/37]AT27.01.2021
FI27.01.2021
HR27.01.2021
LT27.01.2021
LV27.01.2021
RS27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/36]FI27.01.2021
HR27.01.2021
LT27.01.2021
BG27.04.2021
GR28.04.2021
PT27.05.2021
Former [2021/35]FI27.01.2021
HR27.01.2021
LT27.01.2021
PT27.05.2021
Former [2021/33]FI27.01.2021
LT27.01.2021
PT27.05.2021
Cited inInternational search[X]WO2015049063  (DEUTSCHES KREBSFORSCH [DE]) [X] 15* pages 5,14,70; claims 28,30 *;
 [I]  - YVES ALLORY ET AL, "Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome", EUROPEAN UROLOGY, NL, (20140201), vol. 65, no. 2, doi:10.1016/j.eururo.2013.08.052, ISSN 0302-2838, pages 360 - 366, XP055305481 [I] 1-14 * page 363 *

DOI:   http://dx.doi.org/10.1016/j.eururo.2013.08.052
 [A]  - CHRISTIAN KOELSCHE ET AL, "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, (20140411), vol. 33, no. 1, doi:10.1186/1756-9966-33-33, ISSN 1756-9966, page 33, XP021182412 [A] 1-15 * page 35 *

DOI:   http://dx.doi.org/10.1186/1756-9966-33-33
 [I]  - KUN WANG ET AL, "TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR", ONCOTARGET, (20141209), vol. 5, no. 23, doi:10.18632/oncotarget.2660, pages 12428 - 12439, XP055305432 [I] 1-14 * page 12429 - page 12431; figure 2 *

DOI:   http://dx.doi.org/10.18632/oncotarget.2660
by applicantWO2014160834
 WO2015153808
    - BEAUCAGE, SL; IYER, RP, "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach", TETRAHEDRON, (1992), vol. 48, no. 12, doi:doi:10.1016/S0040-4020(01)88752-4, page 2223, XP000915225

DOI:   http://dx.doi.org/10.1016/S0040-4020(01)88752-4
    - HAYFLICK, L; P.S. MOORHEAD, "The serial cultivation of human diploid cell strains", EXP CELL RES, (1961), vol. 25, doi:doi:10.1016/0014-4827(61)90192-6, pages 585 - 621, XP024789652

DOI:   http://dx.doi.org/10.1016/0014-4827(61)90192-6
    - BLACKBURN, E.H., "Structure and function of telomeres", NATURE, (1991), vol. 350, no. 6319, doi:doi:10.1038/350569a0, pages 569 - 73, XP002004674

DOI:   http://dx.doi.org/10.1038/350569a0
    - GREIDER, C.W., "Telomerase is processive", MOL CELL BIOL, (1991), vol. 11, no. 9, pages 4572 - 80
    - SZOSTAK, J.W.; E.H. BLACKBURN, "Cloning yeast telomeres on linear plasmid vectors", CELL, (1982), vol. 29, no. 1, doi:doi:10.1016/0092-8674(82)90109-X, pages 245 - 55, XP023911263

DOI:   http://dx.doi.org/10.1016/0092-8674(82)90109-X
    - GUNES, C.; K.L. RUDOLPH, "The role of telomeres in stem cells and cancer", CELL, (2013), vol. 152, no. 3, pages 390 - 3
    - MURNANE, J.P., "Telomere dysfunction and chromosome instability", MUTAT RES, (2012), vol. 730, no. 1-2, pages 28 - 36
    - CESARE, A.J.; R.R. REDDEL, "Alternative lengthening of telomeres: models, mechanisms and implications", NAT REV GENET, (2010), vol. 11, no. 5, doi:doi:10.1038/nrg2763, pages 319 - 30, XP055166193

DOI:   http://dx.doi.org/10.1038/nrg2763
    - KIM, 'N.W. ET AL., "Specific association of human telomerase activity with immortal cells and cancer", SCIENCE, (1994), vol. 266, no. 5193, doi:doi:10.1126/science.7605428, pages 2011 - 5, XP002138759

DOI:   http://dx.doi.org/10.1126/science.7605428
    - KYO, S. ET AL., "Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers", CANCER SCI, (2008), vol. 99, no. 8, doi:doi:10.1111/j.1349-7006.2008.00878.x, pages 1528 - 38, XP055236338

DOI:   http://dx.doi.org/10.1111/j.1349-7006.2008.00878.x
    - AUBERT, G.; P.M. LANSDORP, "Telomeres and aging", PHYSIOL REV, (2008), vol. 88, no. 2, doi:doi:10.1152/PHYSREV.00026.2007, pages 557 - 79, XP008103401

DOI:   http://dx.doi.org/10.1152/PHYSREV.00026.2007
    - KILLELA, P.J. ET AL., "TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal", PROC NATL ACAD SCI USA, (2013), vol. 110, no. 15, doi:doi:10.1073/pnas.1303607110, pages 6021 - 6, XP055110090

DOI:   http://dx.doi.org/10.1073/pnas.1303607110
    - LIU, X. ET AL., "Highly prevalent TERT promoter mutations in aggressive thyroid cancers", ENDOCR RELAT CANCER, (2013), vol. 20, no. 4, doi:doi:10.1530/ERC-13-0210, pages 603 - 10, XP055110005

DOI:   http://dx.doi.org/10.1530/ERC-13-0210
    - NAULT, J.C. ET AL., "High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions", NAT COMMUN, (2013), vol. 4, page 2218
    - VINAGRE, J. ET AL., "Frequency of TERT promoter mutations in human cancers", NAT COMMUN, (2013), vol. 4, doi:doi:10.1038/ncomms3185, page 2185, XP008168446

DOI:   http://dx.doi.org/10.1038/ncomms3185
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.